The European Commission is taking a look at prostaglandins and their analogues in cosmetic products, noting safety concerns and findings of uneven regulatory application across EU member states.
Announced on 22 June, the Commission will request a safety opinion on prostaglandins and their analogues from the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?